Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 76 Thursday — a welcome improvement, but still short of the 80 or higher score you look for.
Can You Really Time The Stock Market?
IBD's proprietary rating tracks price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating in the early stages of their moves. See if Mineralys Therapeutics can continue to show renewed price strength and hit that benchmark.
Mineralys Therapeutics is building a cup with handle with a 16.90 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Mineralys Therapeutics posted 0% earnings growth in the latest quarterly report, while sales growth came in at 0%. The company is expected to report its latest earnings and sales numbers on or around Aug. 11.
The company earns the No. 257 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, TG Therapeutics and Gilead Sciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
